Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Derived from the plant

THC-JDTetrahydrocannabioctyl (Δ9-THC-JD)

Octyl (C8) homologue of Δ9-THC. A CB1/CB2 agonist in vitro; products sold as « THC-JD » contained mostly Δ8-THC (Munger 2026).

Narcotic: generic clause
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₄H₃₆O₂

CAS 2552798-63-5

Family
Semi-synthetic cannabinoidProvisional classification
Molar mass
356.50 g/mol

Updated on

In plain terms

THC-JD is an « extended » THC: its side chain has eight carbons instead of five. In the laboratory, these long homologues strongly activate the cannabinoid receptors, but no human study exists. Products sold under this name did not even contain the advertised molecule.

Receptors and activity

Target network

CB1Agonistno measured value
  • Activates

The lower the cited value, the closer the target sits to THC-JD: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of THC-JD.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1Agonistno measured value cited
  2. CB2Agonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

THC-JD (tetrahydrocannabioctyl, Δ9-THC-C8) is the octyl-chain homologue of Δ9-THC: eight carbons on the side chain at position 3 instead of five, on the same benzo[c]chromene skeleton (PubChem CID 155318984, synonym « Delta9-THC-JD »). It is promoted as up to « 19 times » more potent than Δ9-THC, a figure that rests on no published measurement. In vitro, in a panel of Δ9-THC homologues from C3 to C8, chain lengthening was the main determinant of signalling efficacy at the CB1 and CB2 receptors, with maximal potency for C7–C8 (Durydivka et al., 2026); a β-arrestin 2 recruitment assay also ranked THC-C8 among the compounds that activate CB1 more than Δ9-THC (Janssens et al., 2024). No pharmacokinetic data or human study have been published. GC-MS analysis of five American vape products labelled « THC-JD », with a Δ8-THC-JD standard, detected the compound in none; the main constituent was Δ8-THC in four samples out of five (Munger et al., 2026). In France, it falls under the generic benzo[c]chromene class in force since 3 June 2024; the Czech Republic (1 July 2024) and Spain (23 April 2025) have listed it by name.

Key sources.

History

Source
Synthetic or semi-synthetic: origin of the commercial product not established

Route of preparation

Chemical process

No characterised biosynthesis; the C8 homologue is not described as an isolated constituent of cannabis in the reference inventories. The commercial product is obtained by synthesis; no open source establishes whether it derives from a cannabinoid extracted from hemp.

Classification

Family, origin and source verification

Family

Semi-synthetic cannabinoid › Provisional classification

Chemistry

C8 side chain · neutral form

Verification

Checked on 20 October 2026; some points still await human review.

Wikipedia (English)

No dedicated article.

References

  1. Munger KR, Bone CCB, Anreise KM, Strongin RM. Analysis of novel cannabis products labeled as containing THC-JD. Cannabis 2026;9(1):1-5 (new tab)PMID 41853707
  2. Durydivka O et al. Side-chain homologs of Δ9-THC, Δ8-THC and HHC reveal pathway bias at CB1R and CB2R. Mol Neurobiol 2026;63:846 (new tab)PMID 42625116
  3. Janssens LK et al. Arch Toxicol 2024;98:2619-2630 (new tab)PMID 38735004
  4. PubChem CID 155318984 (Δ9-THC-C8) (new tab)
  5. Nařízení vlády č. 176/2024 Sb. (new tab)
  6. ANSM, decision of 22/05/2024 (new tab)

Identifiers

Names

Common name
Tetrahydrocannabioctyl (Δ9-THC-JD)
IUPAC name
(6aR,10aR)-6,6,9-trimethyl-3-octyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Other names
THCjd · Δ9-THC-JD · Δ9-THC-C8 · THC-octyl

Identifiers

Formula
C₂₄H₃₆O₂
CAS
2552798-63-5
PubChem CID
155318984(new tab)
InChIKey
SFWRRSGOJSILSQ-WOJBJXKFSA-N
SMILES
CCCCCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.

In the Journal